Omnicare — Q2 2011 Earnings Presentation
18 slides from Omnicare's earnings presentation, Jul 26, 2011
Slide 1: Second Quarter 2011 Financial Results Supplemental Slides
Exhibit 99.2 Second Quarter 2011 Financial Results Supplemental Slides
Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for historical information discussed, the statements made today and listed within the following presentation slides are forward-looking statements that involve risks and uncertainties. Investors are cautioned that such statements are only predictions and that actual
Slide 3: Table of Contents
Table of Contents Second Quarter 2011 Highlights………..……………………..…………….. 4 Operating Metrics - Script Data………………………………………………. 5 Operating Metrics - Bed Data………………………………………………… 6 Adjusted Gross Profit………………...………………………………………...7 Adjusted Net Income…………………………………………..……………… 8 Cash Flows………………………………………………
Slide 4: Second Quarter 2011 Highlights
Second Quarter 2011 Highlights • Gross profit increased 0.4% sequentially to $336.4M on 2.0% increase in sales – Gross margin sequentially lower by 34 bps to 21.62%, reflecting seasonably weaker quarter and full quarter impact of merit increase • Scripts increased 2.0% over 2Q10; 1.0% lower than 1Q1
Slide 5: Operating Metrics: Script Data
Operating Metrics Script Data • Scripts up 2.0% from 2Q10 driven primarily by increased utilization • Sequentially, scripts were down 1.0% reflecting seasonal impact on utilization, census • Generic dispensing rate climbed 60 bps sequentially to 78.0% due primarily to additional generic drug introdu
Slide 6: Operating Metrics: Bed Data
Operating Metrics Bed Data • 8.7% sequential improvement in bed losses, 130 bps sequential improvement in customer retention rate to 93.7% • Beds added by acquisition: • 2Q11 - 0 • 1Q11 - 3,000 • 2Q10 - 2,000 (1) Beds reported as capacity in institutional settings and unique patients serviced in non
Slide 7: Adjusted Gross Profit
Adjusted Gross Profit (1) (2) Excludes special items. A reconciliation of non-GAAP information has been attached to our press release and is also available on our Web site under ‘Supplemental Financial Information’ from the ‘Investors’ page. (3) Includes all scripts dispensed in the Company’s Pharma
Slide 8: Adjusted Net Income
Adjusted Net Income (1),(2) (1) All numbers shown exclude special items and discontinued operations. A reconciliation of non-GAAP information has been attached to our press release and is also available on our Web site under ‘Supplemental Financial Information’ from the ‘Investors’ page. (2) Each am
Slide 9: Cash Flows
Cash Flows(1) • Year-to-date cash flows from operating activities of continuing operations of $280.9M represents the largest cash flow generated in the Company’s history in the first half of the fiscal year. • 2Q11 cash flows benefitted from $23.3 million tax refund • 2Q10 cash flows impacted by $37
Slide 10: Cash Deployment
Cash Deployment • Repurchased an additional 1.25 million shares ($41.3 million) during 2Q11 (in addition to 1.0 million shares repurchased in 1Q11 and 4.4 million repurchased in 2010) • $129 million of authorization remaining under current share repurchase program as of June 30, 2011. • 2Q11 dividen
Slide 11: Capital Structure
Capital Structure Goal is to smooth out maturities to limit refinancing risk, adding to steps already taken in 2010 to improve our flexibility (1) Assumes convertible debentures due 2035 are put to the company in 2015 with related tax recapture included and debt amounts shown are exclusive of unamor
Slide 12: 2011 Guidance
2011 Guidance Previous Guidance (1) Current Guidance (2) • Revenues $6.0B to $6.1B $6.0B to $6.1B • Adjusted Diluted EPS (3) $2.05 to $2.15 $2.05 to $2.15 • Cash Flow from Operations (3) $375M to $425M $400M to $450M Increased cash flow guidance and reaffirmed sales and EPS guidance (Note: original
Slide 13: Longer-Term Targets
Longer-Term Targets (1) Target Double digit three-year CAGR • Adjusted Diluted EPS for the year ending 2013 • Cash Flow from Operations $450 million annually • Capital Returned to Shareholders Approximately 25% per year (2) Focus on continued debt reduction, • Capital Structure management of maturit
Slide 14: Appendix
Appendix 14
Slide 15: Working Capital Management
Working Capital Management 30 20 10 82 76 70 64 T T 58 1Q10 2Q10 3Q10 4Q10 1Q11 2Q11 seem Days of Inventory On Hand (DOH) === Days Sales Outstanding (DSO)
Slide 16: Selected Branded Drug Patent Expirations
Selected Branded Drug Patent Expirations (1),(2) 2Q 2011 3Q-4Q 2011 FY 2012 Aromasin Entocort EC Actos Femara Levaquin IV Detrol Furadantin Susp Arixtra Diovan Concerta Fazaclo Geodon Elastat Gabitril Lexapro Ferrlecit Lipitor Lidoderm Xibrom Primaxin Plavix Carbatrol Uroxatrol Seroquel Nasacort AQ
Slide 17: Second Quarter 2011 Financial Results Supplemental Slides
Second Quarter 2011 Financial Results Supplemental Slides
Slide 18: Slide 18